Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells

Journal of Agricultural and Food Chemistry

Volumn 60, Issue 39, 2012, Pages 9882-9889

  Kim, Sung Hoon ^a   Kim, Bonglee ^a   Kim, Sun Hee ^a   Jeong, Soo Jin ^a,b   Sohn, Eun Jung ^a   Jung, Ji Hoon ^a   Lee, Min Ho ^a  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

apoptosis; Brazilin; HDAC; multiple myeloma; U266

Indexed keywords

ANTI-BACTERIA; ANTI-CANCER AGENTS; ANTI-CANCER MECHANISM; ANTI-INFLAMMATION; ANTICANCER ACTIVITIES; APOPTOSIS INDUCTION; BCL-2 FAMILY PROTEINS; BORTEZOMIB; BRAZILIN; CASPASE-3; CELL CYCLE ANALYSIS; CELL POPULATIONS; CELL-CYCLE ARREST; CHEMOTHERAPEUTIC AGENTS; CYCLIN E; CYCLIN-DEPENDENT KINASE; CYCLIND1; CYTOTOXIC EFFECTS; DOXORUBICIN; END-LABELING; HDAC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONE H3; MRNA LEVEL; MULTIPLE MYELOMA; PHASE ARREST; U266;

ACETYLATION; CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; TRANSCRIPTION FACTORS;

CELL DEATH;

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MULTIPLE MYELOMA; PROTEIN BINDING; PYRAZINES;

CAESALPINIA SAPPAN;

EID: 84867065020     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf302527p     Document Type: Article

References (35)

1. Thirukkumaran, C. M.; Morris, D. G. Oncolytic virotherapy for multiple myeloma: Past, present, and future Bone Marrow Res. 2011, 2011, 632948
2. Barlogie, B.; Epstein, J.; Selvanayagam, P.; Alexanian, R. Plasma cell myeloma-New biological insights and advances in therapy Blood 1989, 73 (4) 865-879
3. Delforge, M.; Blade, J.; Dimopoulos, M. A.; Facon, T.; Kropff, M.; Ludwig, H.; Palumbo, A.; Van Damme, P.; San-Miguel, J. F.; Sonneveld, P. Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues Lancet Oncol. 2010, 11 (11) 1086-1095
4. Galm, O.; Wilop, S.; Reichelt, J.; Jost, E.; Gehbauer, G.; Herman, J. G.; Osieka, R. DNA methylation changes in multiple myeloma Leukemia 2004, 18 (10) 1687-1692
5. Niesvizky, R.; Ely, S.; Mark, T.; Aggarwal, S.; Gabrilove, J. L.; Wright, J. J.; Chen-Kiang, S.; Sparano, J. A. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma Cancer 2011, 117 (2) 336-342
6. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 2007, 25 (1) 84-90
7. Bruserud, O.; Stapnes, C.; Ersvaer, E.; Gjertsen, B. T.; Ryningen, A. Histone deacetylase inhibitors in cancer treatment: A review of the clinical toxicity and the modulation of gene expression in cancer cell Curr. Pharm. Biotechnol. 2007, 8 (6) 388-400
8. Bae, I. K.; Min, H. Y.; Han, A. R.; Seo, E. K.; Lee, S. K. Suppression of lipopolysaccharide-induced expression of inducible nitric oxide synthase by brazilin in RAW 264.7 macrophage cells Eur. J. Pharmacol. 2005, 513 (3) 237-242
9. Moon, C. K.; Lee, S. H.; Lee, M. O.; Kim, S. G. Effects of brazilin on glucose oxidation, lipogenesis and therein involved enzymes in adipose tissues from diabetic KK-mice Life Sci. 1993, 53 (16) 1291-1297
10. Moon, C. K.; Park, K. S.; Kim, S. G.; Won, H. S.; Chung, J. H. Brazilin protects cultured rat hepatocytes from BrCCl3-induced toxicity Drug Chem. Toxicol. 1992, 15 (1) 81-91
11. Kim, S. G.; Kim, Y. M.; Khil, L. Y.; Jeon, S. D.; So, D. S.; Moon, C. H.; Moon, C. K. Brazilin inhibits activities of protein kinase C and insulin receptor serine kinase in rat liver Arch. Pharm. Res. 1998, 21 (2) 140-146
12. Hwang, G. S.; Kim, J. Y.; Chang, T. S.; Jeon, S. D.; So, D. S.; Moon, C. K. Effects of brazilin on the phospholipase A2 activity and changes of intracellular free calcium concentration in rat platelets Arch. Pharm. Res. 1998, 21 (6) 774-778
13. Choi, S. Y.; Moon, C. K. Effects of brazilin on the altered immune functions in the early phase of halothane intoxication of C57BL/6 mice Planta Med. 1997, 63 (5) 400-404
14. Hikino, H.; Taguchi, T.; Fujimura, H.; Hiramatsu, Y. Antiinflammatory principles of Caesalpinia sappan wood and of Haematoxylon campechianum wood Planta Med. 1977, 31 (3) 214-220
15. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 2010, 70 (2) 440-446
16. Yang, X. J.; Seto, E. HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention Oncogene 2007, 26 (37) 5310-5318
17. Hargrove, J. L.; Schmidt, F. H. The role of mRNA and protein stability in gene expression FASEB J. 1989, 3 (12) 2360-2370
18. Singer, R. H.; Penman, S. Messenger RNA in HeLa cells: Kinetics of formation and decay J. Mol. Biol. 1973, 78 (2) 321-334
19. Thakur, V. S.; Gupta, K.; Gupta, S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases Carcinogenesis 2012, 33 (2) 377-384
20. Laubach, J. P.; Mitsiades, C. S.; Mahindra, A.; Schlossman, R. L.; Hideshima, T.; Chauhan, D.; Carreau, N. A.; Ghobrial, I. M.; Raje, N.; Munshi, N. C.; Anderson, K. C.; Richardson, P. G. Novel therapies in the treatment of multiple myeloma J. Natl. Compr. Cancer Network 2009, 7 (9) 947-960
21. Berenson, J. R.; Yellin, O.; Chen, C. S.; Patel, R.; Bessudo, A.; Boccia, R. V.; Yang, H. H.; Vescio, R.; Yung, E.; Mapes, R.; Eades, B.; Hilger, J. D.; Wirtschafter, E.; Hilger, J.; Nassir, Y.; Swift, R. A. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients Br. J. Hamaetol. 2011, 155 (5) 580-587
22. Kim, H. J.; Bae, S. C. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs Am. J. Transl. Res. 2011, 3 (2) 166-179
23. Halkidou, K.; Gaughan, L.; Cook, S.; Leung, H. Y.; Neal, D. E.; Robson, C. N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer Prostate 2004, 59 (2) 177-189
24. Choi, J. H.; Kwon, H. J.; Yoon, B. I.; Kim, J. H.; Han, S. U.; Joo, H. J.; Kim, D. Y. Expression profile of histone deacetylase 1 in gastric cancer tissues Jpn. J. Cancer Res. 2001, 92 (12) 1300-1304
25. Linares, A.; Dalenc, F.; Balaguer, P.; Boulle, N.; Cavailles, V. Manipulating protein acetylation in breast cancer: A promising approach in combination with hormonal therapies? J. Biomed. Biotechnol. 2011, 2011, 856985
26. Tan, J.; Cang, S.; Ma, Y.; Petrillo, R. L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents J. Hematol. Oncol. 2010, 3, 5
27. Cang, S.; Ma, Y.; Liu, D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer J. Hematol. Oncol. 2009, 2, 22
28. Qiu, L.; Burgess, A.; Fairlie, D. P.; Leonard, H.; Parsons, P. G.; Gabrielli, B. G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells Mol. Biol. Cell 2000, 11 (6) 2069-2083
29. 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 Br. J. Cancer 2000, 83 (6) 817-825
30. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 2006, 6 (1) 38-51
31. Johnstone, R. W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer Nat. Rev. Drug Discovery 2002, 1 (4) 287-299
32. Xu, Y. Regulation of p53 responses by post-translational modifications Cell Death Differ. 2003, 10 (4) 400-403
33. Ramalingam, S. S.; Parise, R. A.; Ramanathan, R. K.; Lagattuta, T. F.; Musguire, L. A.; Stoller, R. G.; Potter, D. M.; Argiris, A. E.; Zwiebel, J. A.; Egorin, M. J.; Belani, C. P. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies Clin. Cancer Res. 2007, 13 (12) 3605-3610
34. Badros, A.; Burger, A. M.; Philip, S.; Niesvizky, R.; Kolla, S. S.; Goloubeva, O.; Harris, C.; Zwiebel, J.; Wright, J. J.; Espinoza-Delgado, I.; Baer, M. R.; Holleran, J. L.; Egorin, M. J.; Grant, S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin. Cancer Res. 2009, 15 (16) 5250-5257
35. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer Nat. Rev. Cancer 2005, 5 (10) 761-772